Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if ELVN is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
58 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 9 days ago
Red flags: 0
214 filers reported a long position in ELVN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| FMR LLC | $508.8M | 10M | +46.8% |
| ORBIMED ADVISORS LLC | $343.9M | 6.8M | -14.9% |
| Polar Capital Holdings Plc | $326.4M | 6.4M | +26.9% |
| BlackRock, Inc. | $221.3M | 4.4M | +18.3% |
| Vestal Point Capital, LP | $203M | 4M | +23.1% |
| Commodore Capital LP | $166.2M | 3.3M | Unchanged |
| PRICE T ROWE ASSOCIATES INC /MD/ | $147.4M | 2.9M | +2,870.8% |
| VANGUARD CAPITAL MANAGEMENT LLC | $130.4M | 2.6M | +18.5% |
| CITADEL ADVISORS LLC | $105M | 2.1M | +18.6% |
| Fairmount Funds Management LLC | $94.2M | 1.9M | Unchanged |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.